Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report)'s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.50 and traded as low as $0.41. Elite Pharmaceuticals shares last traded at $0.42, with a volume of 807,140 shares.
Elite Pharmaceuticals Trading Down 0.8%
The company has a quick ratio of 1.90, a current ratio of 3.27 and a debt-to-equity ratio of 0.12. The stock's fifty day moving average price is $0.43 and its two-hundred day moving average price is $0.50. The company has a market capitalization of $464.63 million, a PE ratio of -21.75 and a beta of 0.04.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter. Elite Pharmaceuticals had a negative return on equity of 6.92% and a negative net margin of 25.70%.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Recommended Stories
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
